Publications by authors named "Michael Clearfield"

Claim this Profile
L
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Paul M Ridker, Brendan M Everett, Aruna Pradhan, Jean G MacFadyen, Daniel H Solomon, Michael Clearfield

N Engl J Med· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving Down the Road Less Traveled: The GROUPIE Program at Touro California.
Michael Clearfield

J Am Osteopath Assoc· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Disease as a Result of the Interactions Between Obesity, Climate Change, and Inflammation: The COCCI Syndemic.
Michael Clearfield, Glenn Davis, Jennifer Weiss, Gregory Gayer, Jay H Shubrook

J Am Osteopath Assoc· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public Health and Interprofessional Education as Critical Components in the Evolution of Osteopathic Medical Education.
H Eduardo Velasco-Mondragon, Teresita Menini, Catherine West, Michael Clearfield

J Am Osteopath Assoc· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Path to Osteopathic Distinction: The Touro California GROUPIE Program.
Michael Clearfield

J Am Osteopath Assoc· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fundamentals for an Osteopathic Obesity Designed Study: The Effects of Education on Osteopathic Medical Students' Attitudes Regarding Obesity.
Gregory G Gayer, Jennifer Weiss, Michael Clearfield

J Am Osteopath Assoc· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conversion of Sugar to Fat: Is Hepatic de Novo Lipogenesis Leading to Metabolic Syndrome and Associated Chronic Diseases?
Jean-Marc Schwarz, Michael Clearfield, Kathleen Mulligan

J Am Osteopath Assoc· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.
David Preiss, Ross T Campbell, Heather M Murray, Ian Ford, Chris J Packard, Michael B Clearfield

Eur Heart J· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
S Matthijs Boekholdt, G Kees Hovingh, Samia Mora, Benoit J Arsenault, Pierre Amarenco, Michael B Clearfield

J Am Coll Cardiol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The "New Deadly Quartet" for cardiovascular disease in the 21st century: obesity, metabolic syndrome, inflammation and climate change: how does statin therapy fit into this equation?
Michael Clearfield, Melissa Pearce, Yasmin Nibbe, David Crotty, Alesia Wagner

Curr Atheroscler Rep· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.
S Matthijs Boekholdt, Benoit J Arsenault, G Kees Hovingh, Samia Mora, Terje R Pedersen, Michael B Clearfield

Circulation· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.
Brendan M Everett, Aruna D Pradhan, Daniel H Solomon, Nina Paynter, Jean Macfadyen, Michael Clearfield

Am Heart J· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution or revolution of statin therapy in primary prevention: where do we go from here?
Patricia Rehfield, Colin Kopes-Kerr, Michael Clearfield

Curr Atheroscler Rep· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
S Matthijs Boekholdt, Benoit J Arsenault, Samia Mora, Terje R Pedersen, John C LaRosa, Michael B Clearfield

JAMA· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins in combinations: from ARBITER-6 HALTS to ACCORD--what works?
Michael Clearfield

Curr Atheroscler Rep· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination lipid therapy in type 2 diabetes.
Michael Clearfield

Curr Atheroscler Rep· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
Michael B Clearfield

J Am Osteopath Assoc· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
Naveed Sattar, David Preiss, Heather M Murray, Paul Welsh, Brendan M Buckley, Michael B Clearfield

Lancet· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New evidence extending the benefit of treating LDL-C beyond the current guidelines.
Michael Clearfield

Curr Atheroscler Rep· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rosuvastatin and clinical outcomes in individuals who are not deemed appropriate for baseline statin therapy.
Michael Clearfield

Curr Atheroscler Rep· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention.
Michael Clearfield

Curr Atheroscler Rep· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overweight and obesity: the pathogenesis of cardiometabolic risk.
George A Bray, Michael B Clearfield, Dan J Fintel, Donald S Nelinson

Clin Cornerstone· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study).
Yadong Cui, Douglas J Watson, Cynthia J Girman, Deborah R Shapiro, Antonio M Gotto, Michael B Clearfield

Am J Cardiol· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical practice characteristics of osteopathic and allopathic primary care physicians at academic health centers: results from the National Ambulatory Medical Care Survey.
John C Licciardone, Michael B Clearfield, V James Guillory

Acad Med· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using statins to treat 'healthy' patients: are we there yet?
Bijal M Shah, Robert Kemp, Michael Clearfield

Expert Rev Pharmacoecon Outcomes Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis